Irinotecan and oxaliplatin combination as the first-line treatment for patients with advanced non-small cell lung cancer

[1]  Daniel J Sargent,et al.  A randomized controlled trial of fluorouracil plus leucovorin, irinotecan, and oxaliplatin combinations in patients with previously untreated metastatic colorectal cancer. , 2004, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[2]  I. Hwang,et al.  Combination chemotherapy with irinotecan and cisplatin in elderly patients (>or= 65 years) with extensive-disease small-cell lung cancer. , 2008, Lung cancer.

[3]  Johan Vansteenkiste,et al.  Phase III study comparing cisplatin plus gemcitabine with cisplatin plus pemetrexed in chemotherapy-naive patients with advanced-stage non-small-cell lung cancer. , 2008, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[4]  D. Dunlop,et al.  A phase II study of oxaliplatin and gemcitabine in advanced inoperable stage IIIB/IV non-small cell lung cancer. , 2008, Clinical oncology (Royal College of Radiologists (Great Britain)).

[5]  N. Zilembo,et al.  Oxaliplatin doublets in non-small cell lung cancer: a literature review. , 2008, Lung cancer.

[6]  M. Neubauer,et al.  Phase III open-label comparison of gemcitabine/oxaliplatin versus paclitaxel/carboplatin as first line therapy for advanced non-small cell lung cancer (NSCLC) , 2008 .

[7]  A. Jemal,et al.  Cancer Statistics, 2008 , 2008, CA: a cancer journal for clinicians.

[8]  K. Yoo,et al.  [Cigarette smoking, alcohol consumption, tuberculosis and risk of lung cancer: the Korean multi-center cancer cohort study]. , 2007, Journal of preventive medicine and public health = Yebang Uihakhoe chi.

[9]  Hyunyong Kim,et al.  Combination chemotherapy with irinotecan and cisplatin in elderly patients (>=65 years) with extensive-disease small-cell lung cancer , 2007 .

[10]  E. Halm,et al.  Sex differences in lung cancer survival: do tumors behave differently in elderly women? , 2007, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[11]  N. Saijo,et al.  Randomized phase III study of cisplatin plus irinotecan versus carboplatin plus paclitaxel, cisplatin plus gemcitabine, and cisplatin plus vinorelbine for advanced non-small-cell lung cancer: Four-Arm Cooperative Study in Japan. , 2006, Annals of oncology : official journal of the European Society for Medical Oncology.

[12]  R. Govindan,et al.  A Phase II Study of Irinotecan and Carboplatin in Advanced Non-small Cell Lung Cancer with Pharmacogenomic Analysis: Final Report , 2006, Journal of thoracic oncology : official publication of the International Association for the Study of Lung Cancer.

[13]  K. Hamilton-Nelson,et al.  Efficacy and safety of oxaliplatin and docetaxel in patients with locally advanced and metastatic non-small-cell lung cancer (NSCLC). , 2006, Lung cancer.

[14]  H. Wakelee,et al.  Survival Differences by Sex for Patients with Advanced Non-small Cell Lung Cancer on Eastern Cooperative Oncology Group Trial 1594 , 2006, Journal of thoracic oncology : official publication of the International Association for the Study of Lung Cancer.

[15]  E. Shin,et al.  Comprehensive analysis of UGT1A polymorphisms predictive for pharmacokinetics and treatment outcome in patients with non-small-cell lung cancer treated with irinotecan and cisplatin. , 2006, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[16]  K. Syrigos,et al.  Second-line treatment with irinotecan plus cisplatin vs cisplatin of patients with advanced non-small-cell lung cancer pretreated with taxanes and gemcitabine: a multicenter randomised phase II study , 2005, British Journal of Cancer.

[17]  G. Scagliotti,et al.  The ALPI Trial: The Italian/European Experience with Adjuvant Chemotherapy in Resectable Non–Small Lung Cancer , 2005, Clinical Cancer Research.

[18]  G. Scagliotti,et al.  Phase II study of gemcitabine plus oxaliplatin as first-line chemotherapy for advanced non-small-cell lung cancer , 2005, British Journal of Cancer.

[19]  G. Scagliotti,et al.  Pemetrexed combined with oxaliplatin or carboplatin as first-line treatment in advanced non-small cell lung cancer: a multicenter, randomized, phase II trial. , 2005, Clinical cancer research : an official journal of the American Association for Cancer Research.

[20]  M. Fukuda,et al.  Phase II study of irinotecan combined with carboplatin in previously untreated non-small-cell lung cancer , 2004, Cancer Chemotherapy and Pharmacology.

[21]  Thomas J. Smith,et al.  American Society of Clinical Oncology treatment of unresectable non-small-cell lung cancer guideline: update 2003. , 2004, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[22]  T. Conroy,et al.  An open phase I study assessing the feasibility of the triple combination: oxaliplatin plus irinotecan plus leucovorin/ 5-fluorouracil every 2 weeks in patients with advanced solid tumors. , 2003, Annals of oncology : official journal of the European Society for Medical Oncology.

[23]  S. Kudoh,et al.  Randomised phase III trial of irinotecan combined with cisplatin for advanced non-small-cell lung cancer , 2003, British Journal of Cancer.

[24]  A. Carrato,et al.  Three-week schedule of irinotecan and cisplatin in advanced non-small cell lung cancer: a multicentre phase II study. , 2003, Lung cancer.

[25]  N. Yoshimura,et al.  Phase II study of irinotecan and carboplatin for advanced non-small cell lung cancer. , 2002, Lung cancer.

[26]  D. Fielding,et al.  A multicentre phase II study of cisplatin and gemcitabine for malignant mesothelioma , 2002, British Journal of Cancer.

[27]  David Harrington,et al.  Comparison of four chemotherapy regimens for advanced non-small-cell lung cancer. , 2002, The New England journal of medicine.

[28]  S. Agelaki,et al.  Cisplatin and irinotecan (CPT-11) as second-line treatment in patients with advanced non-small cell lung cancer. , 2001, Lung cancer.

[29]  S. Guichard,et al.  Combination of oxaliplatin and irinotecan on human colon cancer cell lines: activity in vitro and in vivo , 2001, Anti-cancer drugs.

[30]  David H. Johnson,et al.  Phase II study of irinotecan plus cisplatin in patients with advanced non-small-cell lung cancer. , 1999, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[31]  M. Fukuoka,et al.  A phase II trial of combination of CPT-11 and cisplatin for advanced non-small-cell lung cancer. CPT-11 Lung Cancer Study Group. , 1998, British Journal of Cancer.

[32]  J. Armand,et al.  Phase II study of oxaliplatin in poor-prognosis non-small cell lung cancer (NSCLC) , 1998 .

[33]  E. Raymond,et al.  Oxaliplatin: mechanism of action and antineoplastic activity. , 1998, Seminars in oncology.

[34]  C. Tournigand,et al.  Oxaliplatin with high-dose leucovorin and 5-fluorouracil 48-hour continuous infusion in pretreated metastatic colorectal cancer. , 1997, European journal of cancer.

[35]  P. Chollet,et al.  Single agent activity of oxaliplatin in heavily pretreated advanced epithelial ovarian cancer. , 1996, Annals of oncology : official journal of the European Society for Medical Oncology.

[36]  R. Simon,et al.  Optimal two-stage designs for phase II clinical trials. , 1989, Controlled clinical trials.

[37]  J. Armand,et al.  Phase II study of oxaliplatin in poor-prognosis non-small cell lung cancer (NSCLC). ATTIT. Association pour le Traitement des Tumeurs Intra Thoraciques. , 1998, European journal of cancer.

[38]  Y. Nishiwaki,et al.  A phase II study of CPT-11, a new derivative of camptothecin, for previously untreated non-small-cell lung cancer. , 1992, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.